InMode Ltd. (NASDAQ:INMD – Get Free Report) has earned a consensus rating of “Hold” from the eight analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $16.00.
A number of research firms have commented on INMD. Barclays set a $19.00 target price on shares of InMode and gave the company an “overweight” rating in a research report on Thursday, May 7th. Robert W. Baird decreased their target price on shares of InMode from $17.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th.
Get Our Latest Analysis on InMode
Institutional Inflows and Outflows
InMode Trading Down 0.3%
Shares of INMD stock opened at $13.50 on Tuesday. The company’s 50-day moving average price is $13.93 and its 200-day moving average price is $14.18. The stock has a market cap of $855.35 million, a price-to-earnings ratio of 9.93 and a beta of 1.94. InMode has a twelve month low of $12.72 and a twelve month high of $16.74.
InMode (NASDAQ:INMD – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The healthcare company reported $0.25 earnings per share for the quarter, missing the consensus estimate of $0.30 by ($0.05). The firm had revenue of $82.02 million for the quarter, compared to analyst estimates of $79.84 million. InMode had a net margin of 23.27% and a return on equity of 13.47%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.31 EPS.
InMode Company Profile
InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.
InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.
The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.
Featured Stories
- Five stocks we like better than InMode
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.
